Clinical trial · Interventional
EUS-guided Ethanol-lipiodol Ablation of Pancreatic Neuroendocrine Tumor: a Prospective Study
EUS-guided Ethanol-lipiodol Ablation of Pancreatic Neuroendocrine Tumor: a Prospective Feasibility and Long Term Outcome
NCT01902238CI-TRIAL-00024960EUSunknownN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The present study evaluate the safety and efficacy of EUS-guided ethanol-lipiodol ablation for the treatment of pancreatic NET
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Efficacy | — | UNRESOLVED | — |
| Feasibility | — | UNRESOLVED | — |
| Safety | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| EUS-guided ethanol-lipiodol mixture ablation | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- EUS-guided ethanol-lipiodol mixture ablation
- description
- By using 3D-volumetric analysis, the optimal volume of ethanol is calculated by computer estimation of areas on each axial image, using EUS software permitting volume calculation. After calculating optimal ethanol volume by 3D volumetric analysis, we advance the needle into the tumor and inject estimated volume of ethanol/lipiodol (1:1 mixture), typically 1 to 1.5 ml.
- interventionNames
- Procedure: EUS-guided ethanol-lipiodol mixture ablation
Primary outcomes (1)
- measure
- Number of participants with treatment response
- timeFrame
- more than 3 years after procedure
- description
- Final tumor viability will be assessed using contrast enhanced CT, and EUS-guided FNA at 3 years after procedure
Secondary outcomes (1)
- measure
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Pancreas NET(including insulinoma) \< 2cm in diameter * Poor surgical candidate (involving the head of the pancreas or multifocal NET, advanced comorbidity, age \>75 years of age) * Refuse to surgery Exclusion Criteria: * Younger than 18 years of age * Coagulopathy (INR \>1.5, Platelet \<50,000) * Evidence of active pancreatitis * Inability to safely undergo EUS * Refuse to participate
References
Publications (0)
Data not yet available
No reference posted for this study.